CAPSTONE THERAP. DL-,0005 Logo
US14068E2081
A2PRWA
CAPS

CAPSTONE THERAP. DL-,0005

Cargando cotizaciones...

Previsión

Comprar
  1
Mantener
  0
Vender
  0

  • Capstone Energy+ increases production for data centers and expands manufacturing capacity

    Capstone Energy+ reports rising demand from data centers and has expanded manufacturing in Van Nuys from 2 MW to 7 MW per week in single‑shift operation; in two shifts annual capacity could exceed 700 MW. The company highlights its low‑maintenance turbine design, is working on 800‑V‑DC compatibility, lower emissions, a restart of the C250 engine, and a roadmap to 500 kW/1 MW systems. Capstone sees near‑term growth in data centers but also aims to address ports, utilities and substations and is focusing on KWK/KWKK with high heat‑recovery efficiency. After an earlier Chapter‑11 proceeding, management is working with Monarch to clean up the capital structure and expects improvements within about six months. » Más en de.investing.com


  • Capstone secures $10 million convertible note to finance acquisitions

    Capstone Holding Corp. has secured a $10 million convertible note facility to fund its acquisition strategy and drive growth. The first tranche of $3 million will be used to acquire a distributor in the southeastern United States, while the company reaffirms its financial targets for 2025. CEO Matt Lipman highlights the flexibility of the financing and the goal to increase revenue to $100 million. » Más en de.investing.com

En 1998, CAPSTONE THERAP. DL-,0005 ya ha pagado 0,11 € en dividendos. El último pago fue en mayo de 1998.

Datos financieros de la empresa

En el último trimestre, CAPSTONE THERAP. DL-,0005 tuvo unos ingresos de 18,82 M € y un beneficio neto de -1,21 M €
(EUR) junio de 2026
YoY
Ingresos 18,82 M 72,61 %
Beneficio bruto 5,26 M 97,94 %
Beneficio neto -1,21 M 103,60 %
EBITDA 2,31 M 1964,62 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
2,32 M €
Número de acciones
15,2 M
Máximo/mínimo de 52 semanas
1,31 € - 0,15 €
Dividendos No
Beta
-1,50
Ratio P/E
-0,05
Ratio PEG
0,00
Ratio P/B
0,18
Ratio P/S
0,04

Perfil de la empresa

Capstone Therapeutics Corp. ist ein Biotechnologieunternehmen, das neuartige Peptide und andere Moleküle zur Unterstützung von Patienten mit unterversorgten Krankheiten in den Vereinigten Staaten entwickelt. Es entwickelt das Apo-E-mimetische Peptidmolekül AEM-28 und seine Analoga, die klinische Studien der Phase Ia und der Phase Ib/IIa für den Lipoproteinstoffwechsel abgeschlossen haben. Das Unternehmen war früher als OrthoLogic Corp. bekannt und änderte im Mai 2010 seinen Namen in Capstone Therapeutics Corp. Capstone Therapeutics Corp. wurde 1987 gegründet und hat seinen Hauptsitz in Tempe, Arizona.

Nombre
CAPSTONE THERAP. DL-,0005
CEO
Matthew E. Lipman
Sede Alsip, il
Estados Unidos
Sitio web
Salida a bolsa
28/01/1993
Empleados 93

Símbolos bursátiles

Bolsa Símbolo
Pnk
CAPS
🍪

Parqet  usa cookies. Más información